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Abstract By comparing the safety and efficacy of 500 mg of
oral levofloxacin for 3 days with those of intravenous antibi-
otics for 3 days in the prevention of infectious complications
of ultrasound-guided transrectal prostate biopsy (TPB), we
provided a safe and cost-effective infection preventive
protocol for TPB in China. A total of 801 patients with indi-
cations for TPB in 12 centers were randomized into two
groups from October 2011 to December 2015. Patients in
the test group (n = 392) took 500 mg of oral levofloxacin for
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intravenous antibiotics according to the traditional habits of
the center for 3 days. All patients underwent ultrasound-
guided TPB. Infectious complications were compared be-
tween the two groups. Different kinds of antibiotic were used
in the control group. Comparing the two groups, the mean
patient age was 70.6 ± 14.0 and 70.5 ± 14.0 years. The inci-
dence of total infectious complications was 4.6 % (18/392)
and 4.4 % (18/409) respectively, the incidence of asymptom-
atic bacteriuria was 3.1 % (12/392) and 2.7 % (11/409), the
incidence of symptomatic urinary tract infection was 0.0 %
and 0.2 % (1/409), the incidence of fever was 0.8 % (3/392)
and 0.5 % (2/409), the incidence of bacteremia was 0.5 %
(2/392) and 0.0 %, and the incidence of urosepsis was 0.3 %
(1/392) and 1.0 % (4/409) respectively (all P > 0.05). The
selection of antibacterial agents for TPB is in ca haotic condi-
tion in China. Oral levofloxacin at 500 mg once daily for
3 days is a safe, convenient, and cost-effective infection pre-
ventive protocol for TPB in China.
Introduction
As the incidence of prostate cancer increases year by year in
China, ultrasound-guided transrectal prostatic biopsy (TPB)
has become an essential diagnosis method for prostate cancer.
The use of prophylactic antibacterial agents plays an impor-
tant role in reducing postoperative infective complications of
TPB; however, there is no agreement on drug choice and
course of treatment [1], and the choices of antibacterial agents,
administration route, and course of treatment are all in disor-
der in China, which requires more multi-center studies to pro-
vide basis for clinical practice. To prove the efficacy and safe-
ty of levofloxacin 500 mg, po, qd, for 3 consecutive days as a
prophylactic drug in the TPB, we conducted this study in the
department of urology of many centers in China fromOctober
2011 to December 2015.We already published the early result
report of 296 cases in eight centers in China [2]; this report
further expands to 820 cases in 12 centers based on the early
study. This study has been reviewed and approved by the




This is a prospective, multi-center, randomized, control, open-
label clinical study. From October 2011 to December 2015,
patients suspected of prostate cancer requiring TPB were in-
cluded in this study in the department of urology of 12 centers
in China. The subject should meet one of the following
criteria: positive result by digital rectal examination,
PSA > 4 ng/ml, or radiographic examination as suspected
prostate cancer. The subject signed a written informed con-
sent. The main exclusion criteria included: patients with pre-
operative positive urine culture (colony count ≥105 CFU/ml),
preoperative pyuria (routine urine test > 5 WBCs/HPF), pre-
operative fever, disease causing low immunity or patients
using immunosuppressors, coagulation disorders, severe car-
diopulmonary insufficiency, abnormal liver function (ALT or
AST > 2 × upper limits of normal, ULN), abnormal renal
function (serum creatinine > 1.5 × ULN), patients allergic to
test drugs, patients having taken antibacterial agents within
2 weeks before the inclusion, patients with preoperative in-
dwelling urinary catheter, or any condition that the investiga-
tor considered to potentially increase the subject’s risk or in-
terfere the test results.
The bowel preparation was performed by a uniform meth-
od: orally taking metronidazole 400 mg TID 2 days before
biopsy, and discontinuing on the day of biopsy. In addition,
coloclysis was performed with enema (110 ml glycerol en-
emas) before the biopsy. The methods were all ultrasound-
guided TPBs with 10–13 punctures.
Test drugs and dosage regimen
A total of 820 subjects were included in the study, and ran-
domized into test group or control group. Patients in the test
group orally took levofloxacin 500 mg [manufacturer: Daiichi
Sankyo Pharmaceutical (Beijing) Co., Ltd; trade name:
Cravit; Batch No.: 1106G18] on the day of biopsy (1–6 h
before the biopsy) and the first and second day after the biop-
sy, while patients in the control group were given intravenous
antibacterial agents according to the traditional habits of the
center (excluding levofloxacin intravenous injection 500 mg,
QD) on the day of biopsy and the first and second days after
the biopsy.
Table 1 Patients’ demographic and baseline characteristics data
Index Test group Control group P value
(n = 392) (n = 409)
Age (year) 70.6 ± 14.0 70.5 ± 14.8 0.512
Height (cm) 170.2 ± 5.9 170.2 ± 5.8 0.832
Weight (kg) 71.0 ± 10.0 71.0 ± 5.8 0.926
Course of Disease (month) 0.6 ± 2.1 0.5 ± 2.2 0.421
Positive DRE 141 (36.0 %) 141 (34.5 %) 0.658
PSA (ng/ml) 50.1 ± 367.4 49.9 ± 368.3 0.446
DRE: digital rectal examination; PSA: prostate specific antigen
Notes: no difference between two groups for other demographic indica-
tors (body temperature, heart rate, respiratory rate, blood pressure, etc.)
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Study procedures
At 1–2 days before the biopsy, the patient’s demographic char-
acteristics and laboratory test were recorded and then per-
formed the bowel preparation. On the day of biopsy, the sub-
jects were given test drug or control drug according to the
results of randomized grouping. Blood culture was performed
2 h after the biopsy. Patients were followed up on days 1, 2, 3,
and 7–10 after the biopsy. Blood routine, urine routine, and
urine etiological examinations were performed on day 1. On
day 7–10, the blood routine, urine routine, and routine bio-
chemical tests were retested, and the blood or urine bacteriol-
ogy was retested appropriately.
Efficacy and safety evaluation
On day 7–10 after the biopsy, the investigator evaluated the
following indexes:
Primary endpoints: (1) asymptomatic bacteriuria (ASB);
positive urine culture on the morning of the second day after
the biopsy, but the patient had no clinical symptoms, (2)
symptomatic urinary tract infection (symptomatic UTI); pa-
tient with positive urine culture, pyuria, and symptoms of
UTI, (3) fever; body temperature above 38 °C and excluding
other infectious diseases, (4) urosepsis; presenting clinical
symptoms of UTI accompanied with systematic inflammatory
response syndrome, (5) bacteremia; blood culture detects
pathogenic bacteria. Secondary endpoints: (1) use of antibac-
terial agents in control group, (2) cost of antibacterial agents
and the drugs economic benefit cost ratio, (3) incidence of
adverse drug reaction.
Statistical method
The statistical analysis used SAS 9.2 to conduct the analysis;
quantitative statistics were represented by mean ± SD, and
conducted the t-test was conducted; the chi-square test was
applied to enumeration data, with P ≤ 0.05 defined as
significance.
Cost-effectiveness analysis and sensitivity analysis be-
tween the two groups Cost-effectiveness ratio (C/E) repre-
sents the cost per unit effectiveness; a lower ratio means the
cost of increasing by 1 unit of effectiveness is lower, and that
the regimen is more significant in practice. The incremental
cost-effectiveness ratio (ΔC/ΔE) represents the result of cost-
effectiveness comparison between the two groups.
Sensitivity analysis was used to verify the impact of differ-
ent hypotheses or estimates on analysis results. In this analy-
sis, with other costs assumed to be constant, the drug price
decreased 10 %.
Results
A total of 19 of the 820 patients were excluded from the
analysis set due to noncompliance with the main inclusion
criteria. Finally, there were 801 evaluable patients, 392
Table 2 Drugs list for the control
group Type of antibiotics Representative drug Injection/PO N (%)
Second-generation cephalosporins Cefotiam Injection 135 (33.0 %)
Quinolones Ciprofloxacin Injection 118 (28.9 %)
Third-generation cephalosporins Ceftriaxone Injection 19 (4.6 %)
Monocyclic β-lactam Aztreonam Injection 28 (6.8 %)
Compound preparations of penicillins Pipercillin /tazobactam Injection 41 (10.0 %)
Aminoglycosides Streptomycin Injection 7 (1.7 %)
Cephamycins Cefmetazole Injection 61 (14.9 %)
Total 409










Test group (n = 392) 18 (4.6 %) 12 (3.1 %) 0 3 (0.8 %) 2 (0.5 %) 1 (0.3 %)
Control group (n = 409) 18 (4.4 %) 11 (2.7 %) 1 (0.2 %) 2 (0.5 %) 0 4 (1.0 %)
P value 0.8963 0.7528 0.3273 0.6197 0.1481 0.1941
ASB: asymptomatic bacteriuria; UTI: urinary tract infection
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patients in the test group and 409 patients in the control group.
See Table 1 for the patients’ basic clinical data for the two
groups. There was no statistically significant difference be-
tween the two groups for all parameters. (Table 1)
1. Table 2 shows the use of antibiotics in the control group.
2. The overall incidence of infective complications was
4.5 % (36/801), including ASB 2.9 % (23/801), symp-
tomatic UTI 0.1 % (1/801), fever 0.6 % (5/801), bacter-
emia 0.3 % (2/801) and urosepsis 0.6 % (5/801).
Comparison of the infective complications for the two
groups is shown in Table 3. There was no statistically
significant difference for all infective complications (for
all results, P > 0.05). The results of stratified comparison
of infectious complications among the top three drugs
(cefotiam, ciprofloxacin and cefmetazole) in the control
group and the test group are shown in Table 4. The three
drugs were respectively compared with levofloxacin
(500 mg po qd), and there was no statistical difference
in the incidence of infectious complications (P > 0.05).
3. The cost of antibacterial agents of a total of 707 patients
was summarized: 345 cases in the test group and 362
cases in the control group. The mean cost in the test and
control groups was 43.0 ± 3.8 and 402.7 ± 279.2 CNY (1
CNY = 0.1611 USD) respectively (P < 0.001). Table 5
showed the results of mean costs of the two groups and
the cost-effectiveness analysis and sensitivity analysis be-
tween the two groups.
4. Safety analysis
The safety analysis set included 820 patients: 410 patients
in the test group and 410 patients in the control group. No
drug-related adverse events occurred in either group.
Discussion
While using prophylactic antibacterial agents, the incidence of
postoperative infective complications of TPB still exists [3],
including the incidence of symptomatic UTI 2–6 % [4] and
urosepsis 0.1–2.2 % [5]. Our results showed that for patients
with preoperative clean urine, using prophylactic antibacterial
agents and a uniform bowel preparation method, the incidence
of postoperative infective complications was almost similar to
that from international reports.










Levofloxacin (n = 392) 18 (4.6 %) 12 (3.1 %) 0 3 (0.8 %) 2 (0.5 %) 1 (0.3 %)
Cefotiam (n = 98) 4 (4.1 %) 3 (3.1 %) 0 1 (1 %) 0 0
P value* 0.8273 1 0.8018 0.4786 0.6142
Ciprofloxacin (n = 86) 4 (4.7 %) 3 (3.5 %) 0 0 0 1 (1 %)
P value* 0.981 0.837 0.4157 0.5068 0.2376
Cefmetazole (n = 46) 1 (2.1 %) 1 (2.1 %) 0 0 0 0
P value* 0.4463 0.7369 0.5516 0.6273 0.7316
*compare with levofloxacin
ASB: asymptomatic bacteriuria; UTI: urinary tract infection
Table 5 Cost effectiveness
analysis Cost (yuan, C) Effectiveness (%, E) C/E △C/△E
Test group 43.05 95.4 45.1 179825
Control group 402.7 95.6 421.2
Test group Sensitivity analysis 38.745 95.4 40.6 161843
Control group Sensitivity analysis 362.43 95.6 379.1
Effectiveness = 1 – percentage of infective complications, i.e., the percentage of no infective complications
C/E: cost effectiveness ratio, CER
△C/△E: incremental cost effectiveness ratio, ICER
Sensitivity analysis: cost decreased 10 %
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This study also found the current chaotic condition in China
when urologists selected antibacterial agents for TPB. Based on
our study results, 2nd generation cephalosporin (cefotiam,
cefuroxime or the others) had the highest proportion selected
by urologists, followed by fluoroquinolones. This is possibly
because Chinese drug resistance data showed that the fluoroquin-
olone resistance rate ofEscherichia coli inmale urine sample had
exceeded 50 % [6], thus many urologists lacked confidence in
fluoroquinolones. Some urologists selected compound prepara-
tions of penicillins and cephamycins (cefmetazole or cefoxitin),
possibly because of the excessively high isolation rate of the
strain producing extended spectrum β lactamases in China [6].
But it should be noted that all resistance data in China were
mainly from the bacteria of hospital-acquired UTI, not the resis-
tance of community-acquired infectious bacteria, and in addition,
the prophylactic medication was different from treatment medi-
cation, so these high resistance data didn’t completely apply to
the use of prophylactic antibacterial agents. Chiang et al. also
proved that although the fluoroquinolone resistance rate of
Escherichia coli increased, the clinical efficacy showed that
fluoroquinolones were still the main drugs to prevent postopera-
tive infective complications of TPB. The high resistance data
indicate that once infective complications occurred,
fluoroquinolones would not be appropriate to be used in further
treatment [7]. Levofloxacin (500mg, po) shows favourable phar-
macokinetics, excellent penetration into the prostate, good bio-
availability and equivalent oral and parenteral pharmacokinetics
which completely complied with the requirements of the TPB
procedure [8]. Our results also showed that compared with clin-
ically common prophylactic regimens of various intravenous an-
tibacterial agents, levofloxacin 500 mg, po, qd, for 3 consecutive
days showed the same effect in preventing infective complica-
tions, with lower cost and economic advantage. The disadvan-
tage of this study was lack of uniform selection of the antibacte-
rial agent for the control group. In the future, we plan to further
conduct head-to-head controlled studies of levofloxacin in com-
parison with different drugs, and study different courses of treat-
ment with levofloxacin.
In conclusion, from the results we can see that the selection
of antibacterial agent for TPB is in a chaotic condition in China.
We prove that levofloxacin 500 mg po qd for 3 days is a safe,
effective, convenient, and proper prophylactic protocol with
optimal economic benefit cost ratio in the prevention of infec-
tive complications of TPB in China. To our knowledge, this is
the first multi-center study in China in this area.
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